Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Rhea-AI Summary

Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) has announced the pricing of its initial public offering (IPO) of 50,000,000 units at $10.00 per unit, totaling $500 million. Each unit includes one ordinary share and one right to receive one-tenth of an ordinary share upon business combination completion.

The units will trade on Nasdaq under "DMIIU" starting September 25, 2025, with ordinary shares and rights later trading separately under "DMII" and "DMIIR". Underwriters have a 45-day option to purchase up to 7.5 million additional units for over-allotments. Cantor Fitzgerald & Co. serves as the sole book-running manager, with closing expected September 26, 2025.

Positive

• Large IPO size of $500 million indicates strong market interest
• Additional 7.5M unit over-allotment option provides flexibility for market demand
• Listing on major exchange (Nasdaq) provides strong visibility and liquidity

Negative

• SPAC structure means uncertainty about future business combination target
• Investor returns dependent on successful business combination completion
• Potential dilution from rights conversion upon business combination

Insights

SPAC Investment Specialist

$500M SPAC IPO offers investors new acquisition vehicle in pharmaceutical sector with standard 1/10 rights structure.

Drugs Made In America Acquisition II Corp has priced its $500 million SPAC IPO at $10.00 per unit, a standard pricing structure for blank check companies. Each unit includes one ordinary share and one right to receive one-tenth of an ordinary share upon completing a business combination.

The SPAC structure follows the typical pattern we see in the market, with units that will eventually separate into individual tradable securities (DMII and DMIIR). The $500 million raise (potentially extending to $575 million if over-allotment options are exercised) provides substantial acquisition capital for targeting businesses in what appears to be the pharmaceutical or drug manufacturing sector, based on the company name.

The "II" in the company name indicates this is a second SPAC from the same sponsor team, suggesting they have prior experience with this investment vehicle. Cantor Fitzgerald, a well-established investment bank with significant SPAC experience, is serving as the sole book-runner, providing institutional credibility to the offering.

This SPAC joins the market at a time when SPAC activity has moderated from its 2020-2021 peak but continues to offer investors a potential vehicle for accessing private companies transitioning to public markets. As with all SPACs, investors should be aware that the management team typically has 18-24 months to identify and complete a business combination, or they must return the capital to investors.

Fort Lauderdale, FL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) (the “Company”) announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “DMIIU” beginning September 25, 2025. Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols “DMII” and “DMIIR,” respectively. The underwriters have been granted a 45-day option to purchase up to an additional 7,500,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on September 26, 2025, subject to customary closing conditions.

Cantor Fitzgerald & Co. is acting as the sole book-running manager in the offering. Loeb & Loeb LLP is serving as legal counsel to the Company. Ellenoff Grossman & Schole LLP is serving as legal counsel to Cantor Fitzgerald & Co.

A registration statement on Form S-1 (333-288791) relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on September 24, 2025. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 5^th Floor, New York, NY 10022, by email at prospectus@cantor.com, or from the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Drugs Made In America Acquisition II Corp.

The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov.

Contact Information

Drugs Made In America Acquisition II Corp. 
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
Lynn Stockwell
Chief Executive Officer and Executive Chair
Email: executive@dmaacorp.com 
Phone: (954) 870-3099

FAQ

What is the IPO price and size for Drugs Made In America Acquisition II Corp (DMIIU)?

DMIIU priced its IPO at $10.00 per unit for 50,000,000 units, raising a total of $500 million.

When will DMIIU stock begin trading on Nasdaq?

DMIIU units will begin trading on Nasdaq on September 25, 2025 under the ticker symbol 'DMIIU'.

What does each DMIIU unit consist of?

Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination.

Who is the underwriter for the DMIIU IPO?

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the IPO.

What is the over-allotment option for DMIIU's IPO?

Underwriters have a 45-day option to purchase up to 7.5 million additional units to cover over-allotments.